February 28, 2025 | Client News, NASDAQ: EZFL, NASDAQ: HTCR, NASDAQ: LASE, NASDAQ: MIGI, NASDAQ: OKYO, NASDAQ: SPRC, NYSE American: NNVC
TRNR details $50M pro forma annual revenue guidance, rationale of expected Sportstech acquisition, comments on market manipulation concerns and bitcoin as a Treasury asset AUSTIN, TX / ACCESS Newswire / February 27, 2025 / Interactive Strength Inc. (Nasdaq:TRNR) (“TRNR” or the “Company”), maker of innovative specialty fitness equipment under the CLMBR and FORME brands, today […]
May 8, 2024 | Client News, NASDAQ: OKYO
LONDON and NEW YORK, May 08, 2024 (GLOBE NEWSWIRE) — OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing innovative ocular therapies for the treatment of inflammatory dry eye disease (DED), a multi-billion-dollar market, and anterior ocular segment diseases including neuropathic corneal pain (NCP), an ocular condition associated with pain but without an FDA […]
April 30, 2024 | Client News, NASDAQ: OKYO
LONDON and NEW YORK, April 30, 2024 (GLOBE NEWSWIRE) — OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing innovative ocular therapies for the treatment of inflammatory dry eye disease (DED), a multi-billion-dollar market, and anterior ocular segment diseases including neuropathic corneal pain (NCP), an ocular condition associated with pain but without an FDA […]
April 9, 2024 | Client News, NASDAQ: OKYO
LONDON and NEW YORK, April 08, 2024 (GLOBE NEWSWIRE) — OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing innovative ocular therapies for the treatment of inflammatory dry eye disease (DED), a multi-billion-dollar market, and anterior ocular segment diseases including neuropathic corneal pain (NCP), an ocular condition associated with pain but without an FDA […]
April 2, 2024 | Client News, NASDAQ: OKYO
LONDON and NEW YORK, April 02, 2024 (GLOBE NEWSWIRE) — OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing innovative ocular therapies for the treatment of inflammatory dry eye disease (DED), a multi-billion-dollar market, and anterior ocular segment diseases including neuropathic corneal pain (NCP), an ocular condition associated with pain but without an FDA […]
